SecBot SecBot
SECBOTREPLAY Home › Report › PASG

PASG · Passage Bio reported Q4 and full-year 2025 financial results,…

Passage Bio · PRESS-RELEASE filed Mar 3, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Mar 3, 2026 at 07:00 ET

Passage Bio reported Q4 and full-year 2025 financial results, highlighting clinical progress in its upliFT-D trial for frontotemporal dementia, including enrollment in new cohorts and a cash runway extending into Q1 2027. While R&D and net loss decreased year-over-year, no revenue was generated as the company remains pre-revenue with ongoing clinical development.

  • Cash and cash equivalents were $46.3 million as of December 31, 2025, down from $76.8 million in 2024.
  • R&D expenses decreased to $23.3 million in 2025 from $40.2 million in 2024.
  • Net loss narrowed to $45.5 million in 2025 from $64.8 million in 2024.
  • Enrolled first three FTD-GRN patients in Cohort 3 and treated first FTD-C9orf72 patient in Cohort 4 of the upliFT-D study.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access